Objective: A system enabling the objective assessment of the transmission of voice sounds to the external auditory canal (EAC) during phonation has recently been revised. Our aim was to evaluate the effectiveness of this new system in the diagnosis of patulous Eustachian tube (PET) patients by comparing the results obtained using this method with those obtained from conventional objective tests to diagnose PET.
Methods: A prospective survey of medical records was included with definite PET, possible PET, and sensorineural hearing loss as control. The measurement system consists of a personal computer, an AD/DA converter (NI 6361, National Instruments), a probe microphone system for recording voice sound (ER-10C, Etymotic Research) and two microphones for measuring noise sound in the EAC (ER-10B+, Etymotic Research). Pronouncing the "Ni" sound for 5 s were recorded with these three microphones. The ratio of the maximum sound pressure of voice sound and noise sound in EAC (EAC/Voice) was simultaneously calculated, and results were displayed on a personal computer for diagnosing.
Results: Thirty-one patients of 42 ears with definite PET, 26 patients of 38 ears with possible PET, and 12 patients of 24 ears with sensorineural hearing loss as control were included. The EAC/Voice were 8.63 ± 5.43, 25.41 ± 32.63, and 25.87 ± 24.93 in the control, definite PET, and possible PET group respectively. The control group was significantly different from the definite PET (p < 0.05) and possible PET group (p < 0.05). ROC curve analysis confirmed 14.7 as the best diagnostic cut-off value of EAC/Voice (area under the curve=0.782, 95% CI 0.671-0.894). By adopting this cut-off point, 25 (56.8%) and 22 (61.1%) ears were determined as positive findings in the definite PET and possible PET group, respectively. There was no significant correlation between the positive findings judged by the current method and that of sonotubometry in the control (r = -0.63, p = 0.769), definite PET (r = 0.12, p = 0.451), and possible PET group (r = 0.12, p = 0.451).
Conclusion: The current system is more useful in the objective assessment of autophony during phonation by calculating the ratio of voice sound and elicited noise sound transmitted in the EAC (EAC/Voice). This method seems promising because it is able to detect cases eluding conventionally used test methods such as sonotubometry performed without phonation, thereby increasing the accuracy of PET diagnoses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anl.2020.12.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lymph Node Staging and Treatment in Pediatric Patients With Soft Tissue Sarcomas: A Consensus Opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.
Pediatr Blood Cancer
January 2025
Division of Pediatric Surgery, University of Kentucky, Lexington, Kentucky, USA.
Accurate staging of nodal involvement in pediatric sarcoma patients is important to determine correct systemic and local therapy, with the goal to reduce subsequent recurrences. However, differences in lymph node staging strategies, definitions, and treatment protocols between the Children's Oncology Group (COG), European paediatric Soft tissue sarcoma Study Group (EpSSG), and the Cooperative Weichteilsarkom Studiengruppe (CWS) complicate comparisons. In this article, we aim to establish internationally recognized recommendations for lymph node assessment and treatment of children and adolescents diagnosed with rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) according to the Consensus Conference Standard Operating Procedure methodology.
View Article and Find Full Text PDFCT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL).
Radiology
January 2025
From the Department of Radiology, University Hospital Halle, Ernst-Grube-Strasse 40, 06120 Halle (Saale), Germany (D.S., J.S., J.M.B.); Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany (L.K., T.W.G., R.K.); Diagnostic Imaging and Pediatrics, Warren Alpert Medical School, Brown University, Providence, RI (K.M.M.); Department of Pediatric Radiology, Imaging and Radiation Oncology, Core-Rhode Island, Providence, RI (K.M.M.); Department of Oncology, St Jude Children's Research Hospital, Memphis, Tenn (J.E.F.); Department of Pediatric Hematology and Oncology, University Hospital Giessen-Marburg, Giessen, Germany (C.M.K., D.K.); Medical Faculty of the Martin Luther University of Halle-Wittenberg, Halle (Saale) Germany (C.M.K.); Department of Radiology, University of Wisconsin-Madison, Madison, Wis (S.Y.C.); Roswell Park Comprehensive Cancer Center, Buffalo, NY (K.M.K.); Department of Radiation Oncology, Medical Faculty of the Martin-Luther-University, Halle (Saale), Germany (T.P., D.V.); Department of Radiation Oncology, Mayo Clinic-Jacksonville, Jacksonville, Fla (B.S.H.); Department of Radio-Oncology, Medical University Vienna, Vienna, Austria (K.D.); and Department of Radiology, Boston Children's Hospital and Harvard Medical School, Boston, Mass (S.D.V.).
Staging of pediatric Hodgkin lymphoma is currently based on the Ann Arbor classification, incorporating the Cotswold modifications and the Lugano classification. The Cotswold modifications provide guidelines for the use of CT and MRI. The Lugano classification emphasizes the importance of CT and PET/CT in evaluating both Hodgkin lymphoma and non-Hodgkin lymphoma but focuses on adult patients.
View Article and Find Full Text PDFNIRADS-based case assessment of post-treatment head and neck cancer and its clinical correlation: A validation study.
Natl J Maxillofac Surg
November 2024
Associate Professor, Oncopathology, Mahamana Pandit Madan Mohan Malviya Cancer Centre and Tata Memorial Centre, Varanasi, Uttar Pradesh, India.
Introduction: The neck imaging reporting and data system (NIRADS) lexicon is aimed at surveillance of head and neck cancer during post-treatment follow-up using either a CECT or PET-CT scan. These recommendations standardize management, reduce interobserver variability, and standardizes scientific communication.
Objectives: The primary aim of this study was to validate the correlation between the NI-RADS category and disease status on clinical follow-up and histopathological analysis.
Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
Oral Oncol
February 2025
The Ohio State University, Department of Otolaryngology - Head and Neck Surgery, Columbus, OH, USA. Electronic address:
Background: Induction chemotherapy (IC) followed by chemoradiation (CRT) is one treatment approach for patients with locoregionally advanced oropharyngeal squamous cell carcinoma (OPSCC) associated with human papillomavirus (HPV). This pilot study aimed to assess whether a circulating tumor (ct) DNA assay outperforms PET-CT in assessing treatment response in patients with HPV + OPSCC treated with induction chemotherapy (IC) followed by chemoradiation (CRT).
Materials And Methods: Patients treated with IC and definitive CRT for HPV + OPSCC were included.
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
Clin Breast Cancer
December 2024
Medical Oncology and Palliative Care, Department of Medicine, Breast Cancer Disease Oriented Team, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252.
Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.
Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!